What are the differences in outcomes between FOLFOXIRI and FOLFIRI with Bevacizumab for metastatic colon cancer?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18223738
Cited by: 0

Abstract

FOLFOXIRI plus bevacizumab tends to offer improved survival outcomes over FOLFIRI plus bevacizumab in metastatic colorectal cancer, albeit with more extensive toxicity.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Colorectal Cancer Surgical Treatments Intraperitoneal and Appendiceal Malignancies

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
12 January 2026